Table 5.
Changes in physical parameters in healthy subjects (excluding subjects with dyslipidemia, hypertension, and hyperglycemia)
Measurements | Group | 0 weeks | 4 weeks | 8 weeks | 12 weeks | |
---|---|---|---|---|---|---|
Body weight (kg) | Placebo | Values | 69.78±5.65 | 69.76±5.62 | 69.48±28.4 | 69.55±5.76 |
Δ | −0.01±0.11 | −0.29±0.16 | −0.22±0.19 | |||
KPE | Values | 66.35±6.45a | 66.42±6.45 | 66.18±6.55 | 65.92±6.44a | |
Δ | 0.07±0.15 | −0.46±0.23 | −0.44±0.25 | |||
BMI (kg/m2) | Placebo | Values | 27.43±1.37 | 27.43±1.43 | 27.31±1.40 | 27.35±1.45 |
Δ | 0.00±0.05 | −0.12±0.06 | −0.09±0.07 | |||
KPE | Values | 27.09±1.45 | 27.13±1.45 | 26.99±1.34 | 26.91±1.47 | |
Δ | 0.04±0.06 | −0.20±0.09 | −0.18±0.10 | |||
VFA (cm2) | Placebo | Values | 88.33±20.78 | Not measured | 88.55±21.95 | 89.08±19.18 |
Δ | 0.22±1.85 | 0.75±1.77 | ||||
KPE | Values | 84.72±18.26 | Not measured | 83.32±18.06 | 80.42±18.30 | |
Δ | −2.17±1.70 | −4.30±1.40a | ||||
SFA (cm2) | Placebo | Values | 276.21±68.29 | Not measured | 277.29±73.74 | 279.57±73.72 |
Δ | 1.08±4.20 | 3.36±4.40 | ||||
KPE | Values | 263.96±67.76 | Not measured | 267.96±63.89 | 254.43±59.51 | |
Δ | 2.02±4.74 | −9.53±4.56a | ||||
TFA (m2) | Placebo | Values | 364.54±72.51 | Not measured | 365.84±81.04 | 368.65±78.20 |
Δ | 1.30±5.00 | 4.11±5.39 | ||||
KPE | Values | 348.68±71.67 | Not measured | 351.28±64.90 | 334.85±62.79 | |
Δ | −0.15±5.78 | −13.83±5.13a | ||||
TGs (mg/dL) | Placebo | Values | 75.46±23.67 | 81.36±24.56 | 87.54±41.53 | 85.11±29.16 |
Δ | 5.89±3.77 | 12.07±5.72 | 9.64±3.59 | |||
KPE | Values | 70.83±21.30 | 79.38±27.13 | 74.26±25.54 | 69.21±24.59a | |
Δ | 8.54±4.66 | 2.43±3.57 | −1.63±4.71 |
Notes: Values are presented as mean±SD. There were significant differences from the placebo group according to the Student’s t-test (ap<0.05).
Abbreviations: BMI, body mass index; KPE, Kaempferia parviflora extract; SFA, subcutaneous fat area; TFA, total fat area; TGs, triglycerides; VFA, visceral fat area.